Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell Lung Cancer and other solid tumorsLORUSSO, Patricia M; HERBST, Roy S; BJORK, Thomas et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2040-2048, issn 1078-0432, 9 p.Article

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibitionALBANELL, Joan; ROJO, Federico; NICHOLSON, Robert I et al.Journal of clinical oncology. 2002, Vol 20, Num 1, pp 110-124, issn 0732-183XArticle

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well ToleratedLEYLAND-JONES, Brian; COLOMER, Ramon; FUKUSHIMA, Yumi et al.Journal of clinical oncology. 2010, Vol 28, Num 6, pp 960-966, issn 0732-183X, 7 p.Article

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortGIANNI, Luca; EIERMANN, Wolfgang; ANGEL CLIMENT, Miguel et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 377-384, issn 0140-6736, 8 p.Article

Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumorsHANAUSKE, Axel-R; CASSIDY, Jim; SASTRE, Javier et al.Clinical cancer research. 2007, Vol 13, Num 2, pp 523-531, issn 1078-0432, 9 p., 1Article

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyKAUFMAN, Bella; MACKEY, John R; REVIL, Cédric et al.Journal of clinical oncology. 2009, Vol 27, Num 33, pp 5529-5537, issn 0732-183X, 9 p.Article

Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancerFUKUOKA, Masahiro; YANO, Seiji; EEK, Richard et al.Journal of clinical oncology. 2003, Vol 21, Num 12, pp 2237-2246, issn 0732-183X, 10 p.Article

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trialRANSON, Malcolm; HAMMOND, Lisa A; FEYEREISLOVA, Andrea et al.Journal of clinical oncology. 2002, Vol 20, Num 9, pp 2240-2250, issn 0732-183XArticle